Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Bruno Douradinha

Bruno Douradinha

Bruno Douradinha

Associate Professor in Vaccine Technology and Senior Group Leader in Vaccinology

Bruno has joined PSI as an Associate Professor in Vaccine Technology and Senior Group Leader in Vaccinology within the Emerging Pathogens Group, led by Professor Dame Sarah Gilbert. He holds a bachelors degree in Chemical Engineering and a masters degree with Distinction in Biotechnology and a PhD in Biomedical Sciences, bringing over 20 years of experience in vaccine development for Plasmodia, Streptococci, Dengue, Zika, Klebsiella pneumoniae, and HIV.

He has expertise in genetically engineered microorganisms, adenoviral, recombinant protein, and DNA vaccines, in both academic and industry settings (Crucell and Novartis). He played a pivotal role in characterising the p52- mutant Plasmodium parasite in animal models, leading to a human malaria vaccine based on a triple mutant Plasmodium falciparum p52-/p36-/sap1-, which demonstrated safety in clinical trials. His work with the Plasmodium p52-, published in PNAS, earned him the best Microbiology article award from the Instituto Bacteriológico Câmara Pestana in 2006 (Lisbon, Portugal). Bruno also contributed to Zika DNA vaccine design during the 2015/16 epidemic, collaborating with FIOCRUZ in Brazil.

Bruno has numerous publications on vaccine development, infectious diseases, microbiological assay optimisation for GMP, as well as articles on policy and society, in memoriam pieces, scientific hypotheses, and reviews. He also holds patents for novel vaccination strategies.

Bruno has also secured funding from various prestigious bodies, including EMBO, COST, FLAD, the Portuguese Ministry for Science and Education, and Fondazione Ri.MED, among others.

Bruno's research aims to enhance the immunogenicity of the replication-deficient simian adenoviral vectors ChAdOx1 (used in the AstraZeneca/Oxford SARS-CoV-2 vaccine) and ChAdOx2. His ultimate goals are to achieve higher vector immunogenicity, reducing the need for reagents and consumables for a vaccine, positively impacting the environment and increasing vaccine development sustainability levels.